Chonluten is a short synthetic peptide from the Khavinson “bioregulator” family, marketed for the bronchopulmonary system. It is closely related in concept — and confusingly overlapping in commercial descriptions — with Bronchogen. Some Russian-language sources describe Chonluten specifically as a capsule product containing a bronchopulmonary tripeptide/tetrapeptide combination, while English-language reseller sites use the name almost interchangeably with Bronchogen.
Research snapshot
| Peptide category | Khavinson-family short “bioregulator” peptide, marketed for the bronchopulmonary system |
| Primary research interest | Bronchopulmonary/lung tissue support (marketed; not independently confirmed) |
| Highest available evidence | Unverified — closely related in concept and confusingly overlapping in commercial descriptions with Bronchogen; no authoritative primary source consistently resolves which sequence, if any, is specific to Chonluten |
| Human research available | No — no human clinical trial identified |
| Development status | Not in formal pharmaceutical development; sold as a capsule product |
| Regulatory status | Not an approved drug anywhere |
| Last reviewed | September 2026 |
Technical identity
| Primary name | Chonluten |
| Alternative names | Used almost interchangeably with Bronchogen by some English-language resellers, though Russian-language sources describe it as a distinct capsule product |
| Peptide sequence | Not reliably established — sources variously describe it as the tripeptide Glu-Asp-Arg, a related tetrapeptide, or the same Ala-Glu-Asp-Leu (AEDL) sequence used for Bronchogen; no authoritative primary source resolves which applies |
| Amino-acid length | Not reliably established (sources describe either a tripeptide or tetrapeptide) |
| Molecular formula | Not independently verified in this pass |
| Molecular weight | Not independently verified in this pass |
| CAS Registry Number | Not reliably established |
| PubChem CID | Not reliably established |
| Peptide class | Khavinson-group “bioregulator” peptide line |
| Primary biological target | Not established — proposed bronchopulmonary tissue activity, not confirmed via primary literature |
| Developer or originator | Vladimir Khavinson’s laboratory, for the broader bioregulator line |
| Development status | Not an approved or registered pharmaceutical anywhere identified in this review |
What it is
Chonluten belongs to the same short-peptide bioregulator concept developed by Vladimir Khavinson’s laboratory, aimed at the bronchi and lungs. Some sources describe it as containing the tripeptide Glu-Asp-Arg or a related tetrapeptide, while others give it the same Ala-Glu-Asp-Leu (AEDL) sequence used for Bronchogen. PeptideBlog.net could not identify an authoritative primary source that consistently resolves which sequence, if any, is specific to Chonluten versus Bronchogen — vendor material is inconsistent, and this is documented here as an open conflict rather than resolved by picking one answer.
Historically, “Chonluten” appears to trace to a Russian oral-capsule product name used by companies selling Khavinson-derived bioregulators, distinguishing it commercially (if not always chemically, per available sources) from injectable-style “Bronchogen” branding used by some other resellers. Whether this reflects a genuine formulation difference or simply different marketing of the same or similar material could not be confirmed.
No confirmed CAS number, PubChem CID, or UNII record was located for Chonluten. It is not an FDA-approved drug and does not appear to hold clear independent pharmaceutical registration in the U.S.; in Russia it circulates as a “biologically active additive” (supplement) product rather than a prescription medicine as far as could be verified.
How does it work?
Plain-English explanation
The proposed idea, consistent with the broader bioregulator concept, is that Chonluten supports normal bronchial and lung tissue function and turnover, particularly framed by sellers around respiratory aging or chronic bronchial complaints. This is a developer hypothesis, not a demonstrated clinical effect.
Technical explanation
As with related peptides in this family, the proposed mechanism is short-peptide modulation of gene expression in respiratory epithelial cells. This has not been independently validated outside the originating research network, and no pharmacokinetic data for oral use was identified.
Potential benefits and research applications
Bronchopulmonary tissue support
What is being investigated: whether Chonluten supports normal bronchial/lung function, including in chronic bronchitis or age-related respiratory decline, per developer and vendor materials. How the effect might occur: proposed gene-regulatory action in lung tissue. Evidence: limited animal/laboratory data attributed to the originating Russian group; no independent replication identified. Strength: weak (Tier 3/4 at best). Limitation: no controlled human data was found, and the unresolved sequence overlap with Bronchogen makes it unclear whether “Chonluten” research, where it exists, is chemically distinct from Bronchogen research.
What dosage information circulates?
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.
Amounts studied in human research
No established or reliably sourced dosing information was identified.
Amounts studied in animal research
Not consistently reported. General bioregulator-family animal studies are referenced by resellers without extractable, Chonluten-specific dose figures.
Practitioner and community-reported protocols
Reseller pages commonly list 10-20 mg oral capsules, one capsule daily, in cycles of roughly 10-20 days. These figures closely mirror those given for Bronchogen by the same and other vendors. This is vendor/community-reported information (Tier 6), and its original clinical source could not be verified.
What circulates E5
| Reported use | Route | Amount reported | Frequency | Reported length |
|---|---|---|---|---|
| General bronchopulmonary/lung support (community use) | Oral capsule | 10-20 mg per capsule | Once daily | Roughly 10-20 day cycles |
Vendor sources commonly describe 10-20 mg oral capsules taken once daily for about 10-20 days.
These figures are nearly identical to those circulated for Bronchogen by overlapping sellers; the original clinical source, if any, could not be verified.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Side effects, risks, and limitations
No systematic human safety data was identified. As with other unregulated short-peptide oral supplements, concerns include unverified product identity and purity, uncertain oral bioavailability, absence of long-term safety monitoring, and general supply-chain risks. The unresolved Chonluten/Bronchogen naming overlap adds a further identity-verification concern for buyers or researchers trying to compare sources.
Regulatory and developmental status
Chonluten is not FDA approved and has no FDA-recognized indication. No clear independent pharmaceutical registration was identified in Russia; it circulates as a supplement product internationally. Status verified as of the review date below.
Frequently asked questions
What is Chonluten?
Chonluten is a short Khavinson-family synthetic peptide marketed for bronchopulmonary/lung support, sold mainly as an oral capsule.
How is Chonluten different from Bronchogen?
Both are marketed for the respiratory system from the same research family. Vendor sources give inconsistent sequence and formulation information, and PeptideBlog.net could not confirm a reliable chemical distinction between the two names — this is treated as an open conflict rather than resolved.
What dosage has been studied in humans?
No established or reliably sourced human dosing information was identified.
What dosage commonly circulates online?
Vendors commonly describe 10-20 mg oral capsules taken once daily for roughly 10-20 days, nearly identical to figures given for Bronchogen; this is vendor/community-reported, not clinically established.
Is Chonluten approved by any regulator?
No. No FDA or other formal regulatory approval was identified.
Bottom line
Chonluten is another thinly documented member of the Khavinson bioregulator family, and its relationship to the near-identical Bronchogen product could not be cleanly resolved from available sources — this page documents that conflict openly rather than guessing. Whatever underlying research exists comes from the originating Russian group, is limited to animal/mechanistic work, and has not been independently confirmed in humans.